What is the 13F Pro Quality Score for IMMX?

13F Pro ranks Immix Biopharma, Inc. (IMMX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View IMMX's current score at https://13fpro.ai/research/IMMX (free sign-up required for the full ranking).

Where does 13F Pro source IMMX data?

All Immix Biopharma, Inc. fundamentals and ownership data come directly from SEC EDGAR. Immix Biopharma, Inc. files with the SEC under CIK 1873835. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is IMMX in?

Immix Biopharma, Inc. (IMMX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is IMMX research updated on 13F Pro?

IMMX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Immix Biopharma, Inc.(IMMX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1873835 IMMX stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

IMMX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Immix Biopharma, Inc. (IMMX), a Healthcare sector company. IMMX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Immix Biopharma, Inc. reports net income of $-10.1M, free cash flow of $-9.9M. Top institutional holders of IMMX by reported 13-F value include JANUS HENDERSON GROUP PLC, Saturn V Capital Management, EVENTIDE ASSET MANAGEMENT,, based on the most recent SEC filings. IMMX trades on the Nasdaq exchange and files with the SEC under CIK 1873835. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IMMX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Immix Biopharma, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-10.1M

Free Cash Flow

Q1 2026

$-9.9M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

-90.8% YoY

$-29.4MFY 2025

FY21 $-24.4MFY22 $-8.2MFY23 $-15.4MFY25 $-29.4M

Operating Income

-85.6% YoY

$-30.0MFY 2025

FY21 $-1.4MFY22 $-8.2MFY23 $-16.1MFY25 $-30.0M

EPS (Diluted)

+0.0% YoY

$-0.89FY 2025

FY21 —FY22 $-0.59FY23 $-0.89FY25 $-0.89

Total Assets

+426.2% YoY

$104.8MFY 2025

FY21 $18.2MFY22 $14.9MFY23 $19.9MFY25 $104.8M

Op. Cash Flow

-110.4% YoY

$-23.9MFY 2025

FY21 $-1.6MFY22 $-7.4MFY23 $-11.4MFY25 $-23.9M

Metric	FY 2025	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Net Income	$-29.4M -90.8%	$-15.4M -87.4%	$-8.2M +66.2%	$-24.4M -2024.3%	$-1.1M	—
Operating Income	$-30.0M -85.6%	$-16.1M -96.4%	$-8.2M -507.9%	$-1.4M -197.9%	$-453.9K	—
EPS (Diluted)	$-0.89 +0.0%	$-0.89 -50.8%	$-0.59	—	—	—
Total Assets	$104.8M +426.2%	$19.9M +33.7%	$14.9M -18.1%	$18.2M +3271.4%	$539.6K	—
Operating Cash Flow	$-23.9M -110.4%	$-11.4M -53.5%	$-7.4M -366.1%	$-1.6M -292.7%	$-404.7K	—

AI Insight: IMMX Financial Trends

Equity jumped to $84M in Q1 2026, but operating losses hit a record -$11M as cash burn accelerates sharply.

• Revenue is sporadic: two isolated $20M quarters (Q1 2025, Q1 2026) with zero revenue in all other periods.

• Operating losses nearly doubled from -$5M in Q2 2024 to -$11M in Q4 2025 and Q1 2026.

• Operating cash outflow worsened from -$1M in Q4 2024 to -$11M in Q4 2025 and -$10M in Q1 2026.

• Equity surged from $13M in Q4 2024 to $84M in Q1 2026, suggesting significant new capital raised.

⚠ Revenue appears in only two quarters over eight; sustainability of the $20M recurring pattern is unconfirmed.

⚠ Cash burn reached -$10M to -$11M in the last two quarters; runway depends entirely on the fresh equity infusion.

AI Insight: IMMX Ratio Trends

Immix Biopharma remains deeply loss-making with no revenue base, though TTM operating margin of -180.4% versus Q1 2026's -54.0% suggests lumpy, one-off cash burn rather than a linear improvement.

• Q1 2026 operating margin of -54.0% compares to Q1 2025's -23.4%, indicating year-over-year burn acceleration on a single-quarter basis.

• ROA improved from -91.3% in Q1 2025 to -42.1% in Q1 2026, suggesting modest asset-efficiency gain over four quarters.

• D/E is absent across all periods, limiting leverage assessment; no debt load visible may reflect equity-only financing typical of early-stage biotechs.

⚠ TTM operating margin of -180.4% is far worse than Q1 2026's -54.0%, signaling a large one-off expense in recent quarters worth investigating.

⚠ ROE swung from -162.9% in Q3 2024 to -47.8% in Q1 2026; equity raises diluting the denominator could flatter this ratio going forward.

Get alerted when IMMX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Immix Biopharma, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of IMMX

JANUS HENDERSON GROUP PLC
$43.7M4,802,002 sh
Saturn V Capital Management LP
$33.6M3,693,585 sh
EVENTIDE ASSET MANAGEMENT, LLC
$23.2M2,549,019 sh
VANGUARD CAPITAL MANAGEMENT LLC
$16.3M1,787,994 sh
MILLENNIUM MANAGEMENT LLC
$15.9M1,750,200 sh
MARSHALL WACE, LLP
$15.0M1,641,552 sh
Logos Global Management LP
$11.2M1,225,000 sh
Bleichroeder LP
$9.1M1,000,000 sh
FRANKLIN RESOURCES INC
$8.8M969,066 sh
Velan Capital Investment Management LP
$6.7M740,000 sh

Fund	Value	Shares
JANUS HENDERSON GROUP PLC	$43.7M	4,802,002
Saturn V Capital Management LP	$33.6M	3,693,585
EVENTIDE ASSET MANAGEMENT, LLC	$23.2M	2,549,019
VANGUARD CAPITAL MANAGEMENT LLC	$16.3M	1,787,994
MILLENNIUM MANAGEMENT LLC	$15.9M	1,750,200
MARSHALL WACE, LLP	$15.0M	1,641,552
Logos Global Management LP	$11.2M	1,225,000
Bleichroeder LP	$9.1M	1,000,000
FRANKLIN RESOURCES INC	$8.8M	969,066
Velan Capital Investment Management LP	$6.7M	740,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put IMMX on your watchlist

Track score changes the day Immix Biopharma, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is IMMX a good stock to buy?

13F Pro's AI-powered analysis of Immix Biopharma, Inc. (IMMX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IMMX are available on the IMMX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own IMMX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IMMX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Immix Biopharma, Inc.'s investment landscape.